Gene vectors delivered

Ett antal genvektorer levererades till CombiGene den 4 november från Auckland-baserade företaget GeneDetect®. Genvektorerna blir nu föremål för en serie ex vivo- och in vivo-studier som på CombiGenes uppdrag sker på Lunds Universitet och Köpenhamns Universitet, med målet att välja en kandidat-vektor för fortsatt utveckling till en behandling av epilepsipatienter.
Läs mer >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99



CombiGene AB, Agavägen 52A, SE-181 55 Lidingö


Linked In     Twitter      Facebook